{
  "docId": "019de073-f22f-749b-aa66-140061a622d8",
  "docSlug": "bfa8f27558bcf20e1dab95d83263e96b",
  "documentTitle": "Berkeley Lights | Investor Day Presentation Deck | 91 slides",
  "authorId": "berkeley-lights",
  "authorName": "Berkeley Lights",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 57,
  "pageCount": 91,
  "prevPage": 56,
  "nextPage": 58,
  "slideType": "propose_solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "The slide uses a structured layout to connect problem, solution, and business impact.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-f22f-749b-aa66-140061a622d8/57",
  "deckHref": "/decks/019de073-f22f-749b-aa66-140061a622d8",
  "deckJsonHref": "/decks/019de073-f22f-749b-aa66-140061a622d8.json",
  "deckAnchorHref": "/decks/019de073-f22f-749b-aa66-140061a622d8#slide-57",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.3,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "list",
      "text": "Challenges in current state: Transient cell lines are difficult to scale up, with lower yields and higher batch-to-batch variability leading to high COGS. Current stable producer cell line workflows are time-consuming and expensive.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "06c4f7e2-af01-42d1-91a7-d21faa8ce577",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.7,
        "y": 0.35
      },
      "kind": "list",
      "text": "How we will achieve this: License the platform to CDMO's and innovators to screen cell lines. Partner with cell line innovators to rapidly develop a full suite of proprietary stable producer cell lines.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1d76d41f-2ee3-4f86-8f19-cb989e1ecc5d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.38,
        "y": 0.65
      },
      "kind": "list",
      "text": "Business model: Platform license fees from customers developing their own cell lines, Product license fees for BLI-owned cell lines, Limited fee-for-service development of stable producer cell lines",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "34a6c225-082e-4d6a-8385-cb6ae0c6d8af",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.3,
        "x": 0.05,
        "y": 0.65
      },
      "kind": "list",
      "text": "BLI value proposition: Stable producer cell line development technology on a significantly reduced timeline—comparable to current development timelines for transient cell lines",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "39b9127d-d40f-4b14-9173-83b2f68313f8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.38,
        "y": 0.35
      },
      "kind": "list",
      "text": "What this means for customers: Significantly reduced timelines for cell line development, Improved productivity and yield, Reduced COGS",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d0b965b5-1795-4d13-9f6f-58ec9d8cfebd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.7,
        "y": 0.8
      },
      "kind": "metric",
      "text": "~$550-1,250M by 2025",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e1e2e60d-38f2-447f-a441-11fa37eea663",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Expert interviews, EvaluatePharma pipeline analysis, cell and gene therapy customer survey.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a8c9064-1eb8-4d95-ae61-b78018db296c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Berkeley Lights' cell line development platform can address industry bottlenecks in AAV manufacturing",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e03e5c8a-e17a-4b05-81ed-ceeb7a9d0baf",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "before-after-framing",
      "slug": null,
      "matchId": "d63f917e-a1a5-48f1-b6d0-573ff3d80514",
      "evidence": "Contrasts current industry challenges with the proposed BLI solution and its benefits.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 80,
      "from": 45,
      "beatId": "0e318181-28dc-401d-b762-c3ba1b0a4abe",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The document presents Berkeley Lights' technology and growth strategy as a solution to the presented problems",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 59,
      "from": 51,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "5881ba67-4f39-4100-b1e0-beb09a566b20",
      "evidence": "The document presents the potential benefits of Berkeley Lights' technology in reducing costs and improving efficiency",
      "position": 0,
      "objective": "Highlight the cost of inaction in gene therapy manufacturing",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}